Target intelligence / Profile preview

nucleophosmin 1 pseudogene 30 (NPM1P30)

Target
NPM1P30
Molecular classification
Other (Pseudogene)
01

Overview

**Nucleophosmin 1 pseudogene 30 (NPM1P30)** is a genomic sequence in the human genome that resembles the functional **NPM1** gene but contains mutations or deletions (such as premature stop codons or frameshifts) that prevent it from encoding a functional protein[2][4]. As a pseudogene, NPM1P30 is generally considered a non-functional remnant of gene duplication or retrotransposition events. Unlike its parent gene NPM1—which encodes an essential nucleolar protein involved in ribosome biogenesis, the cell cycle, and multiple cancer-associated processes—NPM1P30 does not encode any active protein product and is not attributed with independent biological functions or therapeutic relevance[1][4]. There is no current evidence that NPM1P30 acts as a disease biomarker or a therapeutic drug target. Pseudogenes in general may sometimes regulate gene expression through RNA mechanisms (such as acting as microRNA decoys or regulators of parent gene transcripts), but specific regulatory roles for NPM1P30 have not been established in the literature and its disease or drug relevance is unreported[2][4]. **Key distinctions:** - NPM1P30 is not equivalent to the functional protein NPM1 (nucleophosmin 1), and does not share NPM1’s broad biological roles in ribosome assembly, genomic stability, cell cycle, or disease (especially hematologic malignancies)[1][3][5]. - Its designation as a pseudogene means NPM1P30 is not a member of major protein families or receptor classes relevant to drug targeting, such as G protein-coupled receptors, ion channels, enzymes, or transcription factors[4]. - No drugs or mechanisms of action are known to interact with NPM1P30, nor are there safety or biomarker considerations. If you intended to refer to the functional *NPM1* gene/protein (and not the pseudogene), that is a clinically significant oncogenic driver in acute myeloid leukemia, but "NPM1P30" is strictly a pseudogene and is not a therapeutic target[1][3][5].

Other names
nucleophosmin 1 (nucleolar phosphoprotein B23, numatrin) pseudogene 30nucleophosmin-likeNPM1P30

Beyond the preview

Go deeper on nucleophosmin 1 pseudogene 30 (NPM1P30).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nucleophosmin 1 pseudogene 30 (NPM1P30).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call